- Home
- TLNC vs EDIT Comparison
TLNC vs EDIT Comparison
Compare TLNC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLNC | EDIT |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.3M | 368.6M |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | TLNC | EDIT |
|---|---|---|
| Price | $10.27 | $2.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.10 |
| AVG Volume (30 Days) | 130.4K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $10.00 | $1.66 |
| 52 Week High | $11.30 | $3.94 |
Technical Indicators
Market Signals| Indicator | TLNC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 47.62 |
| Support Level | $10.20 | $2.35 |
| Resistance Level | $10.30 | $2.91 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.00 | 38.24 |
Price Performance
Historical ComparisonAbout TLNC Talon Capital Corp. Class A Ordinary Shares
Talon Capital Corp is a newly organized blank check company.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.